At a glance
- Originator GlaxoSmithKline
- Class Anxiolytics
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 14 Dec 1995 Preclinical development for Anxiety disorders in United Kingdom (unspecified route)